Pernilla Sandwall has a Pharmacy degree from Uppsala University.
Pernilla has a solid background in drug development, including clinical studies, regulatory processes, business development and financing in a life science company in a listed environment. Most recently, she came from a role as COO, Chief Operating Officer, at InDex Pharmaceuticals, where she has been active since 2012 and has taken the company and its pharmaceutical projects from phase II to phase III. Prior to that, Pernilla was at Merck & Co. for more than 20 years. Inc. (MSD), where she worked with clinical research activities at both the subsidiary in Sweden and at the head office in the USA.
Other ongoing assignments: Board member of Alzinova AB and Innovative Minor Life science companies (IML, which is part of the industry organization Läkemedelsindustriföreningen).
Number of shares: 776,500 and 280,000 warrants (TO6)